Related Experiment Video

Updated: Jul 24, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K

Rechallenge of afatinib for EGFR-mutated non-small cell lung cancer previously treated with osimertinib: a

Taisuke Araki1, Shintaro Kanda2, Masamichi Komatsu1

  • 1First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.

Translational Lung Cancer Research
|July 10, 2023
PubMed
Abstract

Insights

This study investigates afatinib rechallenge for non-small cell lung cancer (NSCLC) patients resistant to first-line osimertinib. Afatinib may offer a new treatment option for EGFR-mutated NSCLC after osimertinib failure.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have transformed advanced non-small cell lung cancer (NSCLC) treatment.
  • Osimertinib is a standard first-line therapy for EGFR-mutated NSCLC, but resistance is common, creating an unmet need for subsequent treatments.
  • Afatinib, a second-generation EGFR-TKI, shows potential against specific EGFR mutations and in case reports for post-osimertinib resistance.

Purpose of the Study:

  • To evaluate the efficacy and safety of afatinib rechallenge in patients with advanced or recurrent non-squamous NSCLC following first-line osimertinib resistance.
  • To establish a potential treatment strategy for a patient population with limited options after osimertinib failure.

Main Methods:

  • Phase II, single-arm, multicenter clinical trial.
  • Inclusion criteria: advanced/recurrent non-squamous NSCLC, EGFR mutations (exon 19 deletion or L858R), prior first-line osimertinib and non-TKI second-line chemotherapy, and comprehensive genomic profiling.
  • Primary endpoint: objective response rate. Secondary endpoints: progression-free survival, overall survival, and tolerability. Patient recruitment begins December 2023.

Main Results:

  • This section is to be filled upon study completion.

Conclusions:

  • The study aims to provide evidence for afatinib rechallenge as a subsequent treatment option after first-line osimertinib resistance in EGFR-mutated NSCLC.
  • Results may support the incorporation of afatinib into treatment algorithms for this specific patient group.
Keywords:
Non-small cell lung cancer (NSCLC)afatinibepidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)osimertinibrechallenge

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.1K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
202
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
209
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K